Abstract
Antibody-drug conjugates (ADCs) are emerging as effective tools in cancer therapy, combining the antibody's exquisite specificity for the target antigen-expressing cancer cell together with the cytotoxic potency of the payload. Much success stems from the rational design of "toxic warheads", chemically linked to antibodies, and from fine-tuning the intricate properties of chemical linkers. Here, we focus on the antibody moiety of ADCs, dissecting the impact of Fab, linkers, isotype and Fc structure on the anti-tumoral and immune-activating functions of ADCs. Novel design approaches informed by antibody structural attributes present opportunities that may contribute to the success of next generation ADCs.
| Original language | English |
|---|---|
| Article number | e1395127 |
| Pages (from-to) | e1395127-e1395127-11 |
| Number of pages | 12 |
| Journal | OncoImmunology |
| Volume | 7 |
| Issue number | 3 |
| Early online date | 20 Nov 2017 |
| DOIs | |
| Publication status | Published - 2018 |
Access to Document
- Antibody structure and engineering_HOFFMAN_Publishedonline20November2017_GOLD VoR (CC BY)
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.